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Cyclic nucleotide phosphodiesterases (PDEs) are a su-
perfamily of enzymes controlling cellular concentra-
tions of the second messengers cAMP and cGMP. Crystal
structures of the catalytic domains of cGMP-specific
PDE5A1 and cAMP-specific PDE4D2 in complex with
the nonselective inhibitor 3-isobutyl-1-methylxanthine
have been determined at medium resolution. The cata-
lytic domain of PDE5A1 has the same topological folding
as that of PDE4D2, but three regions show different
tertiary structures, including residues 79–113, 208–224
(H-loop), and 341–364 (M-loop) in PDE4D2 or 535–566,
661–676, and 787–812 in PDE5A1, respectively. Because
H- and M-loops are involved in binding of the selective
inhibitors, the different conformations of the loops, thus
the distinct shapes of the active sites, will be a determi-
nant of inhibitor selectivity in PDEs. IBMX binds to a
subpocket that comprises key residues Ile-336, Phe-340,
Gln-369, and Phe-372 of PDE4D2 or Val-782, Phe-786,
Gln-817, and Phe-820 of PDE5A1. This subpocket may be
a common site for binding nonselective inhibitors of
PDEs.
Cyclic nucleotide phosphodiesterases (PDEs)1 hydrolyze
cAMP and cGMP to 5-AMP and 5-GMP. The second messen-
gers, cAMP and cGMP, mediate the response of cells to a wide
variety of hormones and neurotransmitters and modulate
many metabolic processes such as cardiac and smooth muscle
contraction, glycogenolysis, platelet aggregation, secretion, li-
polysis, ion channel conductance, apoptosis, and growth control
(1–6).
The human genome encodes 21 PDE genes and over 60 PDE
isoforms categorized into 11 families (7–16). PDE molecules
contain three regions: an N-terminal splicing region, a regula-
tory domain, and a catalytic domain near the C terminus. The
11 PDE families share a conserved catalytic domain of about
300 amino acids but rare homology in other regions across
families. The function of the N-terminal splicing region of the
PDE families is unknown. The regulatory domains of PDEs
contain various structural motifs such as a calmodulin-binding
domain in PDE1, upstream conserved region in PDE4, PAS
(period clock protein, aryl hydrocarbon receptor nuclear trans-
locator, and single-minded protein) domain in PDE8, GAF
(cGMP-specific PDE, adenylyl cyclase, and Fh1A) domain in
PDE2, -5, -6, -10, and -11. The regulatory domains have been
shown to play roles in the regulation of the catalytic activity of
PDEs or to participate in cross-talk with other signaling path-
ways (16–18).
PDEs share high degree (25–49%) of amino acid conserva-
tion in the catalytic domains, implying a similar three-dimen-
sional structure of the catalytic domains. However, PDE fam-
ilies and isoforms within the respective family have varying
substrate preferences for cAMP and cGMP. The PDE4, -7, and
-8 families prefer to hydrolyze cAMP, whereas PDE5, -6, and -9
are cGMP-specific. PDE1, -2, -3, -10, and -11 show activities
toward both substrates but have distinct Km values for cAMP
and cGMP (16). In addition, many PDE families possess selec-
tive inhibitors that bind to the conserved active site. For exam-
ple, rolipram is a PDE4-selective inhibitor, and sildenafil
(VIAGRATM) is a PDE5-selective inhibitor (19).
In the past 3 decades, selective inhibitors of PDEs have been
widely studied as therapeutics such as cardiotonics, vasodila-
tors, smooth muscle relaxants, antidepressants, antithrombot-
ics, antiasthmatics, and agents for improving cognitive func-
tions such as learning and memory (20–24). Many PDE
inhibitors have been in clinical trials or have already entered
the marketplace. For example, the PDE3-selective inhibitor
cilostazol (PletalTM) is a drug for the reduction of symptoms of
intermittent claudication, and the PDE5 inhibitors sildenafil
(ViagraTM), vardenafil (LevitraTM), and tadalafil (CialisTM) are
used for treatment of male erectile dysfunction. Selective in-
hibitors of PDE4 have been studied as anti-inflammatory drugs
for asthma and chronic obstructive pulmonary disease (24–30).
Extensive biochemical, pharmacological, and clinical studies
have been performed on PDEs and their selective inhibitors.
However, the mechanisms by which the conserved active sites
of PDEs recognize a common inhibitor and distinguish selective
inhibitors remain mysteries. Structural studies on the catalytic
domain of unligated PDE4B (31), PDE4D in complex with
inhibitor zardavarine (32), PDE4D2 in complex with rolipram
(33) and AMP (34), and PDE5A in complex with sildenafil (35)
have provided preliminary understanding of inhibitor selectiv-
ity. Here we report the structures of the catalytic domains of
human PDE5A1 and PDE4D2 in complex with a nonselective
inhibitor 3-isobutyl-1-methylxanthine (IBMX). These struc-
tures reveal a common subpocket in the active site of PDEs for
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FIG. 1. Structures of the PDE-IBMX complexes. A, ribbon diagram of PDE4D2-IBMX. The -helices are colored as cyan, and blue color
represents 310 helices. The first metal ion is interpreted as zinc, as discussed previously (31, 33), whereas the second metal ion (Me2) is ambiguous.
B, ribbon diagram of PDE5A1-IBMX. The second metal ion was assigned as magnesium because 0.2 M MgSO4 was used in the crystallization buffer.
C, the structural superposition between PDE4D2 and PDE5A1. The cyan ribbons represent the conserved core structures between PDE4D2 and
PDE5A1. The variable regions are drawn in gold for PDE4D2 and green for PDE5A1. D, the correspondence of amino acid sequence to the secondary
structures.
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binding of this nonselective inhibitor. Structural comparison
between PDE4 and PDE5 suggests that conformational differ-
ence, in addition to the specific amino acid determinants, is
another mechanism of inhibitor selectivity.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—The catalytic domain of human
PDE4D2 (BF059733) was expressed in Escherichia coli and purified as
described previously (33). The cDNA of the catalytic domain of human
PDE5A1 was generated by site-directed mutagenesis of the bovine
PDE5A1 gene. The coding regions for amino acids 535–860 of PDE5A1
were amplified by PCR and subcloned into the expression vector
pET15b. The resultant plasmid pET-PDE5A1 was transformed into
E. coli strain BL21 (Codonplus) for overexpression. The E. coli cell
carrying pET-PDE5A1 was grown in LB medium at 37 °C to A600  0.7,
and then 0.1 mM isopropyl -D-thiogalactopyranoside was added for
further growth at 15 °C overnight. Recombinant PDE5A1 was purified
by nickel-nitrilotriacetic acid affinity column (Qiagen), thrombin cleav-
age, Q-Sepharose (Amersham Biosciences), and Sephacryl S300 (Amer-
sham Biosciences) columns. The PDE5A1 protein had purity greater
than 95% as shown by SDS-PAGE. A typical batch of purification
yielded over 10 mg of PDE5A1 from a 2-liter cell culture. The fragment
of human PDE5A1 expressed in E. coli had a catalytic activity of about
2 mol/min/mg, which is comparable with that of the protein expressed
in a baculovirus system (36).
Crystallization and Data Collection—Crystals of PDE4D2-IBMX and
PDE5A1-IBMX were grown by hanging drop. The catalytic domain of 15
mg/ml PDE4D2 (amino acids 79–438) in a storage buffer of 50 mM
NaCl, 20 mM TrisHCl (pH 7.5), 1 mM -mercaptoethanol, and 1 mM
EDTA was mixed with 5 mM IBMX. The PDE4D2-IBMX complex was
crystallized against a well buffer of 0.1 M HEPES (pH 7.5), 20%
PEG3350, 30% ethylene glycol, 10% isopropyl alcohol, and 5% glycerol
at 4 °C. The well buffer was used as the cryosolvent for freezing the
crystals in liquid nitrogen. Diffraction data were collected on beamline
14C at Advanced Photon Source (Table I). The PDE4D2-IBMX crystal
has the space group P212121 with cell dimensions of a  99.3, b  112.5,
and c  160.9 Å. The catalytic domain of 10 mg/ml PDE5A1 (amino
acids 535–860) was mixed with 5 mM IBMX and crystallized against a
well buffer of 0.1 M Trisbase (pH 7.5), 17% PEG3350, and 0.2 M MgSO4
at room temperature. To freeze the crystals in liquid nitrogen, the
FIG. 1—continued
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cryosolvent was prepared by mixing 20% glycerol with the well buffer.
Diffraction data of PDE5A1-IBMX were collected on beamline X12C at
National Synchrotron Light Source (Table I). It has the space group
P3121 with cell dimensions of a  b  74.5, and c  130.1 Å. All data
were processed by program HKL (37).
Structure Determination—The PDE4D2 tetramer from the PDE4D2-
rolipram structure (33) was directly applied to solve the structure of
PDE4D2-IBMX, and the orientation of the tetramer was optimized by
rigid body refinement of CNS (38). The structure of PDE5A1-IBMX was
solved by molecular replacement program AMoRe (39), using the cata-
lytic domain of PDE4D2 as the initial model and a data set collected on
Raxis IV to 2.5-Å resolution. The translation search yielded a corre-
lation coefficient of 0.182 and R-factor of 0.526 for 3247 reflections
between 4 and 8 Å resolution. The amino acid differences between
PDE5A1 and PDE4D2 were replaced, and the atomic model was rebuilt
by program O (40) against the electron density map that was improved
by the density modification package of CCP4 (41). The structure was
refined by CNS (Table I). The coordinates have been deposited in the
Protein Data Bank (accession codes 1RKO and 1RKP).
RESULTS AND DISCUSSION
Overall Structures—The crystallographic asymmetric unit of
PDE4D2 in complex with IBMX contains four catalytic do-
mains (residues 79–438) that form a tetramer. The monomer of
PDE4D2-IBMX consists of 16 helices (Fig. 1) that fold into
three subdomains as described previously in the structures of
PDE4B (31) and PDE4D2-rolipram (33). The catalytic domain
of PDE5A1 (residues 535–860) contains 16 helices and has the
same folding topology as that of PDE4D2 (Fig. 1). The crystal of
PDE5A1 contains one catalytic domain in the crystallographic
asymmetric unit, which apparently exists as a monomer. This
is consistent with the biochemical studies that the monomeric
fragment of bovine PDE5A (residues 508–865) has similar
catalytic activity as the full-length PDE5A (36). The electron
density showed that residue 778 of PDE5A1 is better modeled
with leucine instead of isoleucine in the wild type PDE5A1
sequence. The interpretation of this observation is not clear,
but it may be caused by spontaneous mutation during PCR.
The superposition of the catalytic domains of PDE5A1 over
PDE4D2 showed an root mean square deviation of 1.5 Å for the
C atoms of 257 superimposable residues. However, the root
mean square deviation increases to 4.8 Å if the entire catalytic
domain is compared (312 residues). Three regions show differ-
ent tertiary structures and are not superimposable, in addition
to residues 289–298 in PDE4D2, which become a short connec-
tion with deletion of 6 residues in PDE5A1. The N-terminal
regions of residues 79–113 in PDE4D2 and 535–566 in
PDE5A1 contain two helices but have a totally different three-
dimensional arrangement. The region of residues 208–224 in
PDE4D2 and 661–676 in PDE5A1, which is labeled as H-loop
in Fig. 1, shows differences of over 7 Å for the C atom positions
of two short helices H8 and H9. Besides, the H-loop of PDE5A1
is flexible, although traceable in electron density, as shown by
an average B-factor of 71.8 Å2 in comparison with 36.6 Å2 for
all atoms of the structure. The region of residues 341–364 in
PDE4D2 or 787–812 in PDE5A1 (M-loop in Fig. 1) shows
dramatic conformational differences. Nine residues 341–349 at
the tail of helix H14 in PDE4D2 are unfolded into coil or
random conformations in PDE5A1. Residues 793–807 in
PDE5A1 are not traceable due to lack of electron density and
presumably exist in random conformation, in contrast to the
ordered conformations of the corresponding sequences in
PDE4D2.
It is interesting to note that our structure of PDE5A1-IBMX
shows some conformational differences from those of PDE5A in
complex with the inhibitors such as sildenafil. Although the
structure of PDE5A-sildenafil is not available for a detailed
comparison, the paper by Sung et al. (35) reported that residues
665–675 of the H-loop are disordered, and the M-loop is or-
dered in the PDE5A-sildenafil structure. In contrast, our struc-
ture of PDE5A1-IBMX shows that the H-loop is traceable, but
the M-loop is disordered. One possible interpretation of these
differences may be that bindings of each of the different inhib-
itors selectively affect the conformations of these loops. Be-
sides, we note that the catalytic activity of our recombinant
fragment 535–860 of PDE5A1 (2 mol/min/mg) is about 800
times higher than that of the fragment 537–860 for the
PDE5A-sildenafil structure (0.0025 mol/min/mg) (35). Never-
theless, the structural studies by the two groups imply that the
conformational flexibility of H- and M-loops may play roles in
inhibitor selectivity.
Metal Binding—Two metal-binding sites have been assigned
in the crystal structures of PDE4B and PDE4D2 as follows: one
is zinc and another is ambiguous (31, 33, 34). Two metal sites
are also found in the structure of PDE5A1 and occupy the same
location as in the PDE4 structures (Fig. 1). In the PDE5A1
structure, the strongest peak in the 2Fo  Fc map has about 10
times the background and is assigned as zinc, despite the fact
that no zinc was added during expression, purification, and
crystallization of PDE5A1. This site coordinates with His-617,
His-653, Asp-654, Asp-764, and two bound water molecules.
These six coordinations form an octahedron and are the same
as in PDE4 (31, 33). The role of the equivalent residues His-607
and His-643 of bovine PDE5 in metal coordination was estab-
lished by site-directed mutagenesis (42). The second metal ion
forms an octahedron with Asp-654 and five bound water mol-
ecules and has the same coordinations as in PDE4D2. The
second metal ion is assigned as magnesium in the crystal
because 0.2 M MgSO4 was used in crystallization. The crystal-
lographic refinement showed that both metal ions have the
B-factors comparable with the overall average B-factor of the
protein atoms (Table I), in support of the assignment. However,
the physiological metal ions await to be identified. Biochemical
studies have suggested that zinc is the optimal divalent cation
for supporting catalysis in PDE5A1 (43).
IBMX Binding—The electron density maps that were calcu-
lated from the PDE4D2 and PDE5A1 structures without IB-
MXs show that IBMX binds to a subpocket of the active site of
PDEs (Fig. 2). The majority of IBMX-binding residues are
conserved between PDE4 and PDE5. Thus, the xanthine ring of
IBMX stacks against Phe-372 of PDE4D2 or Phe-820 of
TABLE I
Statistics on diffraction data and structure refinement
Data collection
PDE5A1-IBMX PDE4D2-IBMX
Space group P3121 P212121
Unit cell (a, b, c, Å) 74.5, 74.5, 130.1 99.7, 111.7, 159.4
Resolution (Å) 2.05 2.1
Total measurements 211,071 754,083
Unique reflections 27,018 94,246
Completeness (%) 100.0 (100.0)a 91.0 (64.4)a
Average I/ 13.4 (4.9)a 18.9 (3.3)a





Resolution (Å) 50–2.05 50–2.1
Reflections 25,797 89,970
r.m.s.d.b for bond 0.0059 Å 0.0059
r.m.s.d. for angle 1.20o 1.09o
Average B-factor (Å2)
All atoms 36.6 (2674)c 32.8 (10,987)
Protein 36.6 (2541) 32.8 (10,726)
IBMX 27.5 (16) 58.9 (64)
Waters 35.1 (133) 27.8 (189)
Metals 32.1 (2) 42.0 (8)
a The numbers in parentheses are for the highest resolution shell.
b r.m.s.d., root mean square deviation.
c The number of atoms is listed in the parentheses.
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PDE5A1 on one side and contacts hydrophobic residues Ile-336
and Phe-340 of PDE4D2 or Val-782 and Phe-786 of PDE5A1 on
another side. IBMX forms a hydrogen bond with the side chain
of Gln-369 in PDE4D2 or Gln-817 in PDE5A1, in addition to
hydrophobic interactions with Leu-319 and Asn-321 of
PDE4D2 or Leu-765 and Ala-767 of PDE5A1.
On the other hand, IBMX shows some distinct interactions in
the two PDE structures. First, O-6 of IBMX forms a hydrogen
bond with N-2 of Gln-817 in PDE5A1, but with a water mol-
ecule in PDE4D2. Second, the xanthine ring of IBMX shows a
translational shift of about 2 Å when the protein structures of
PDE4D2 and PDE5A1 are superimposed (Fig. 2). Third, the
FIG. 2. IBMX binding. Stereoview of the electron density for IBMX bound to PDE4D2 (A) and PDE5A1 (B). The 2Fo  Fc maps were calculated
from the structures omitted IBMX and contoured at 1.5 for PDE4D2 and 2.0 for PDE5A1. C, chemical structure of IBMX. D, IBMX binding to
the active site of PDE4D2. The xanthine group stacks against Phe-372 and forms hydrogen bond with Gln-369 (dotted lines). E, IBMX binding to
the active site of PDE5A1.
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isobutyl group of IBMX has different orientations in the two
structures and interacts with different residues as follows:
Phe-786 of PDE5A1 but Met-273 and Ile-376 of PDE4D2. Fi-
nally, IBMX shows unique interactions with Met-273 and Met-
357 in PDE4D2 but with Ile-768 in PDE5A1.
At the protein level, the amide group of the Gln-817 side
chain of PDE5A1 has an opposite orientation from that of
Gln-369 of PDE4D2. The configuration of the side chain amide
group of Gln-817 in PDE5A1 is apparently fixed by the hydro-
gen bond to the side chain of Gln-775 that in turn forms
hydrogen bonds with N-1 of Trp-853 and the backbone car-
bonyl oxygen of Ala-767. However, the torsion angle for the
amide side chain of Gln-369 in PDE4D2 is about 180o different
from Gln-817 of PDE5A1. This configuration of the Gln-369
side chain appears to be essential for formation of hydrogen
bonds with Oh1 of Tyr-329 and N-7 of IBMX and is also ob-
served in the structure of PDE4D2-rolipram (33).
The conservation of the majority residues for the IBMX bind-
ing agrees in general with the biochemical studies that IBMX is
a nonselective inhibitor for various PDEs (44). The extra hy-
drogen bond between O-6 of IBMX and Gln-817 of PDE5A1
may account for the slightly higher potency of IBMX in PDE5
(IC50  10 M) (45) than that in PDE4 (IC50  31 M) (46). We
speculate that four residues of Ile-336, Phe-340, Gln-369, and
Phe-372 of PDE4D2 or Val-782, Phe-786, Gln-817, and Phe-820
of PDE5A1 may define a subpocket for the common binding of
nonselective inhibitors of most PDEs. However, it is not clear
why IBMX shows significant variations on orientation in the
structures of PDE4D2 and PDE5A1. One possible interpreta-
tion may be that the active sites in different PDE families
possess the key conserved components for binding of the non-
selective inhibitor IBMX but have slightly different shapes and
sizes. The conformational variation of the active sites in differ-
ent PDE families may thus require an adjustment of the IBMX
orientation to make the best fit in each PDE family. In other
words, the conformation of the active site is a determinant for
binding of inhibitors.
Implication for Inhibitor Selectivity—Selective inhibitors of
PDE families have been widely studied as therapeutic agents
for various human diseases. Enhancement of selectivity is crit-
ical for reducing side effects of the drugs. The structure of
PDE4D2 in complex with rolipram showed a good conservation
of the most rolipram-binding residues, but a few of them mu-
tate dramatically across PDE families (33). This suggests that
variation of the active site residues may selectively distinguish
inhibitors according to their chemical groups, and therefore the
chemical nature of the active site residues may be a determi-
nant for inhibitor selectivity.
On the other hand, structural comparison between PDE4
and PDE5 suggests that different shapes of the active sites may
also be a determinant of inhibitor selectivity. The structure of
PDE5 shows three regions having different conformations from
PDE4. Whereas the N-terminal region of 79–113 of PDE4D2 is
apparently too far to directly contribute to inhibitor selectivity,
H-loop (residues 208–224 of PDE4D2 or 661–676 in PDE5A1)
and M-loop (residues 341–364 in PDE4D2 or 787–812 in
PDE5A1) are located near the active site. H-loop does not
directly contact IBMX and the PDE4-selective inhibitor rolip-
ram (33) but constitutes an edge of the active site. The different
conformations of H-loops will make different shapes and sizes
of the active sites in PDE4D2 and PDE5A1, thus impacting
selective binding of inhibitors. Recent work on the structures of
PDE5-sildenafil proposed that Tyr-664 in the H-loop is in-
volved in interaction with sildenafil (35), supporting a role for
the H-loop in selective binding of PDE5 inhibitors. On the other
hand, Met-357 of the M-loop (residues 341–364) in PDE4D2
forms hydrophobic interactions with the cyclopentane ring of
the PDE4-selective inhibitor rolipram (33), indicating its role in
binding of the selective inhibitor. In contrast, the correspond-
ing residues 787–812 of PDE5A1 show significantly different
conformations: the unfolding of C-terminal end of helix H14
and disordered conformation of 793–807 in PDE5A1 (Fig. 1).
Therefore, the M-loop would have different contact patterns
when interacting with PDE5 inhibitors from the mode in
PDE4. In summary, our structural study suggests that both the
conformation of the active site and the chemical nature of the
residues in contact with the inhibitors contribute to the
selectivity.
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